We are developing our lead product candidate, zilucoplan (formerly RA101495 SC), a potent, synthetic, macrocyclic peptide C5 inhibitor, formulated for convenient, self-administered, subcutaneous, or SC, injection, which is an injection into the tissue under the skin, for the treatment of various complement-mediated diseases, including generalized myasthenia gravis, or gMG, paroxysmal nocturnal hemoglobinuria, or PNH, and other complement-mediated disorders.

There is a clear association between ferritin level above 200 and higher mortality. However, anything below 200 seems to be fine. Do you have some evidence that ferritin should be lowered even below 200?

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Klein-Nulend, J., van Oers, R. F. M., Bakker, A. D. & Bacabac, R. G. Nitric oxide signaling in mechanical adaptation of bone. Osteoporosis Int. 25, 1427–1437 (2014).

We are a development stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any known trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial information to not necessarily be indicative of future operating results or financial conditions. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this “Operating and Financial Review and Prospects.”

We are subject to extensive government regulation and the failure to comply with these regulations may have a material adverse effect on our operations and business.

Our operating history is limited to pre-clinical and clinical development of one product, and our operations to date have been limited primarily to research and development, raising capital and recruiting scientific and management personnel and third-party partners. Therefore, it may be difficult to evaluate our business and prospects. We have not yet demonstrated an ability to commercialize or obtain regulatory approval for any product candidate. Consequently, any predictions about our future performance may not be accurate, and you may not be able to fully assess our ability to complete development and/or commercialize Aramchol, and any future product candidates, obtain regulatory approvals or achieve market acceptance or favorable pricing for Aramchol and any future product candidates.

Regarding exercise and calcification, I read the paper when it was mentioned 2 weeks ago, and there were many things not measured. Those doing the most running are fueling themselves how? Probably carb loading etc, but nobody is measuring insulin, especially Kraft insulin assays. The person most responsible for publicizing Kraft’s work in recent times is Irishman Ivor Cummins. He’s “only an engineer” (albeit with a biochem and problem-solving background) but more and more MDs are paying attention to him. Measures of hyperinsulinemia are much better predictors of CVD than cholesterol etc. (Also, CAC scores are king as Paul Rivas mentioned.)http://www.thefatemperor.com/blog/2015/5/10/lchf-the-genius-of-dr-joseph-r-kraft-exposing-the-true-extent-of-diabetes

A lovely article, Derek, breath of fresh air after the parade of news stories that are muddled whenever they’re not vague. I wish there were a browser plugin that linked a real explanation (curated by angels) whenever you see a science-related news story, especially health-related.

        Share-based compensation is recognized as an expense in the financial statements based on the grant date fair value over the requisite service period. For awards granted to employees and directors that vest based on service conditions, we use the straight-line method to allocate compensation expense to reporting periods. Beginning in the first quarter of 2017, we do not adjust stock-based compensation for estimated forfeitures and account for forfeitures when they occur.

Wang, J. & Yu, G. Biomedical mechanisms of blood stasis syndrome of coronary heart disease by systems biology approaches. Chin J Integr Med. 20, 163–169 (2014).

        Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.